Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

8 reports from 8 outlets in 1 language · first reported 2026-10-01 07:30 UTC · updated 2026-10-02 02:38 UTC · JSON

Reports

1. Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesPublished by chathamdailynews.ca, recorder.ca, standard-freeholder.com, intelligencer.ca · 2026-10-01 07:33 UTC
2. Experimental Survodutide Cut Weight Up to 13.1% in Adults with Type 2 Diabetes in Boehringer's Phase 3 Trialmedicaldaily.com · en · 2026-10-02 02:38 UTC
3. Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesfinanznachrichten.de · en · 2026-10-01 08:33 UTC
4. Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesGlobeNewswire — public companies · en · 2026-10-01 07:30 UTC
5. Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesGlobeNewswire — all · en · 2026-10-01 07:30 UTC